AstraZeneca Pauses Vaccine Trial for Safety Review
NY Times
SEPTEMBER 8, 2020
The company halted late-stage trials of its coronavirus vaccine because of a serious suspected adverse reaction in a participant.
NY Times
SEPTEMBER 8, 2020
The company halted late-stage trials of its coronavirus vaccine because of a serious suspected adverse reaction in a participant.
Pharmaceutical Technology
DECEMBER 7, 2022
Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 6, 2022
The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.
pharmaphorum
DECEMBER 9, 2020
Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.
pharmaphorum
JANUARY 18, 2021
Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. The clinic in question switched to another lot of Moderna vaccine after closing for a few hours.
Pharmacy Times
JANUARY 4, 2023
Children who experienced COVID-19-induced multisystem inflammatory syndrome did not experience severe adverse reactions following COVID-19 vaccination.
STAT
SEPTEMBER 7, 2022
Moving forward, the company will expand patient monitoring in the trial to watch for low magnesium levels, which had resulted in a serious adverse reaction in one study participant that led the FDA to suspend testing earlier this year. Food and Drug Administration on changes to the study’s plan , BioPharma Dive writes. Moving
Let's personalize your content